Back

Prevention of incident atrial fibrillation in type 2 diabetes: nationwide target trial emulation of SGLT2 inhibitors versus GLP-1 receptor agonists

28 August 2026 (11:33 - 11:45)
Organised by: Logo
Congress Presentation Part of: Atrial fibrillation: epidemiology, prevention, and clinical outcomes Prevalence and Incidence of Atrial Fibrillation ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Gal Tsaban

Mayo Clinic, Rochester (United States of America)

4 More presentations in this session

Presentation thumbnail
Impact of CPAP therapy adherence on atrial fibrillation recurrence and progression in patients with severe obstructive sleep apnea
Assistant Professor P. Kalaydzhiev (Sofia, BG)
Abstract Slides Video
Presentation thumbnail
Effects of integrated lifestyle management before pulmonary vein isolation on quality of life – results from the POP-AF RCT
Mr J. Vermeer (Eindhoven, NL)
Abstract Slides Video
Presentation thumbnail
Real-world outcomes of hospital-detected atrial fibrillation. Results from the Scotland-wide treatment & outcomes in atrial fibrillation: real-world data LINkaGe (STARLING) cohort study
Doctor T. Pana (Aberdeen, GB)
Presentation thumbnail
Epicardial adipose layer in the control of cardiomyocyte ion homeostasis: Persistent atrial fibrillation, and semaglutide regulations
Ms R. Basdas (Santiago de Compostela, ES)
Abstract Slides Video

Access the full session

Session thumbnail
Atrial fibrillation: epidemiology, prevention, and clinical outcomes
Video

The Event

Event poster

ESC Congress 2026

28 August 2026 11:33 CET
You may be interested in
thumbnail
Congress Presentation
SGLT2i and AF
31 August 2025
thumbnail
Congress Presentation
Cardiovascular outcomes in sustained use of glucagon like peptide inhibitors: a trial inspired population vs. a broad population
29 August 2025
thumbnail
Congress Presentation
Empagliflozin to prevent post-operative atrial fibrillation in patients undergoing coronary artery bypass graft surgery (EMPOAF), a randomized, double-blind, placebo-controlled trial
28 August 2026
thumbnail
Congress Session
Meet the Experts: how to lower cardiovascular disease risk in patients with diabetes
29 August 2022

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources